The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database

被引:58
作者
Joish, VN
Donaldson, G
Stockdale, W
Oderda, GM
Crawley, J
Sasane, R
Joshua-Gotlib, S
Brixner, DI
机构
[1] Univ Utah, Coll Pharm, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT 84108 USA
[2] AstraZeneca LP, Wilmington, DE USA
关键词
absenteeism; gastroesophageal reflux disease; peptic ulcer disease; productivity; work loss;
D O I
10.1185/030079905X38240
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this study was to examine the relationship of work loss associated with gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) in a large population of employed individuals in the United States (US) and quantify the economic impact of these diseases to the employer. Methods: A proprietary database that contained workplace absence, disability and workers' compensation data in addition to prescription drug and medical claims was used to answer the objectives. Employees with a medical claim with an ICD-9 code for GERD or PUD were identified from 1 January 1997 to 31 December 2000. A cohort of controls was identified for the same time period using the method of frequency matching on age, gender, industry type, occupational status, and employment status. Work absence rates and health care costs were compared between the groups after adjusting for demographic, and employment differences using analysis of covariance models. Results: There were significantly lower (p < 0.05) prescription, and outpatient costs in the controls compared to the disease groups, although the eta-square values were very low. The mean work absence attributed to sick days was 2.8 (+/- 2.3) for controls, 3.4 (+/- 2.5) for GERD, 3.2 (+/- 2.6) for PUD, and 3.2 (+/- 2.3) days for GERD + PUD. For work loss, a significantly higher (p < 0.05) rate of adjusted all-cause absenteeism and sickness-related absenteeism were observed between the disease groups versus the controls. In particular, controls had an average of 1.2 to 1.6 days and 0.4 to 0.6 lower all-cause and sickness-related absenteeism compared to the disease groups. The incremental economic impact projected to a hypothetical employed population was estimated to be $3441 for GERD, $1374 for PUD, and $4803 for GERD + PUD per employee per year compared to employees without these diseases. Conclusions: Direct medical cost and work absence in employees with GERD, PUD and GERD + PUD represent a significant burden to employees and employers.
引用
收藏
页码:535 / 543
页数:9
相关论文
共 23 条
[1]   The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden [J].
Agréus, L ;
Borgquist, L .
PHARMACOECONOMICS, 2002, 20 (05) :347-355
[2]  
[Anonymous], 2000, The practical guide: Identification, evaluation, and treatment of overweight, and obesity in adults
[3]   PROTEINURIA - CHANGES AND MECHANISMS IN TOXIC NEPHROPATHIES [J].
BERNARD, A ;
LAUWERYS, RR .
CRITICAL REVIEWS IN TOXICOLOGY, 1991, 21 (05) :373-405
[4]  
Cohen J., 1988, STAT POWER ANAL BEHA
[5]   The burden of illness of gastro-oesophageal reflux disease: impact on work productivity [J].
Dean, BB ;
Crawley, JA ;
Schmitt, CM ;
Wong, J ;
Ofman, JJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (10) :1309-1317
[6]   Comorbidity measures for use with administrative data [J].
Elixhauser, A ;
Steiner, C ;
Harris, DR ;
Coffey, RN .
MEDICAL CARE, 1998, 36 (01) :8-27
[7]  
Everhart JE, 1998, AM J EPIDEMIOL, V147, P529
[8]  
Frank L, 2000, DIGEST DIS SCI, V45, P809, DOI 10.1023/A:1005468332122
[9]   Pharmaceuticals - Cost or investment? An employer's perspective [J].
Goetzel, RZ ;
Ozminkowski, RJ ;
Meneades, L ;
Stewart, M ;
Schutt, DC .
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2000, 42 (04) :338-351
[10]   Health and productivity management: Establishing key performance measures, benchmarks, and best practices [J].
Goetzel, RZ ;
Guindon, AM ;
Turshen, IJ ;
Ozminkowski, RJ .
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2001, 43 (01) :10-17